Pretomanid Gets Panel Endorsement As Part Of Regimen, Not Individual Molecule, For Treatment-Resistant Tuberculosis

 
• By Michael Cipriano
  
FDA Advisory Committee Feature image
The Antimicrobial Drugs Advisory Committee voted 14-4 supporting approval of the pretomanid regimen.

More from US FDA Performance Tracker

More from Regulatory Trackers